Search
IDEAYA Biosciences Inc
IDYAAdd to Watchlist
37.270USD
+0.720+1.97%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.54BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.97%
5 Days
+6.76%
1 Month
+26.47%
6 Months
+7.81%
Year to Date
+7.81%
1 Year
+77.31%
Key Figures
36.430Open
37.440High
1.59MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.81%Turnover Ratio
36.550Prev. Close
34.840Low
48.52MTurnover
LossP/E Static
3.49P/B
0.00%Div Yield TTM
-13.14%ROA
39.28052wk High
0.80Volume Ratio
-274.48MNet Profit
87.86MShares
-1.5790EPS TTM
-0.05Beta
-14.28%ROE
19.26052wk Low
7.11%Amplitude
100.00%Gross Margin
3.54BMarket Cap
9.19Reward/Risk
2.86%Risk Rate
TradingKey Stock Score of IDEAYA Biosciences Inc
Currency: USD Updated: 2026-06-30Key Insights
IDEAYA Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 52.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
IDEAYA Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
IDEAYA Biosciences Inc Highlights
StrengthsRisks
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 835.26% year-on-year.
Undervalued
The company’s latest PE is -23.60, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 97.55M shares, decreasing 11.71% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 438.18K shares of this stock.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
52.500
Target Price
+43.64%
Upside Space
IDEAYA Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
IDEAYA Biosciences Inc Info
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Ticker SymbolIDYA
CompanyIDEAYA Biosciences Inc
CEOHata (Yujiro S)
Websitehttps://www.ideayabio.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of IDEAYA Biosciences Inc (IDYA)?
The current price of IDEAYA Biosciences Inc (IDYA) is 37.27.
What is the symbol of IDEAYA Biosciences Inc?
The ticker symbol of IDEAYA Biosciences Inc is IDYA.
What is the 52-week high of IDEAYA Biosciences Inc?
The 52-week high of IDEAYA Biosciences Inc is 39.28.
What is the 52-week low of IDEAYA Biosciences Inc?
The 52-week low of IDEAYA Biosciences Inc is 19.26.
What is the market capitalization of IDEAYA Biosciences Inc?
The market capitalization of IDEAYA Biosciences Inc is 3.27B.
Is IDEAYA Biosciences Inc (IDYA) currently rated as Buy, Hold, or Sell?
According to analysts, IDEAYA Biosciences Inc (IDYA) has an overall rating of Buy, with a price target of 52.50.
What is the Earnings Per Share (EPS TTM) of IDEAYA Biosciences Inc (IDYA)?
The Earnings Per Share (EPS TTM) of IDEAYA Biosciences Inc (IDYA) is -1.28.